by Daniel Schwartz | Nov 28, 2022 | Clinical Trials, Health Policy
CLINICAL TRIALS Should patients with diabetes, CKD and proteinuria despite RAASi & SGLT2i be considered for add-on therapy with finerenone (triple therapy)? A recent Twitter thread: As a Canadian nephrologist, relevant & active national debate in light of...
by Daniel Schwartz | Aug 19, 2015 | Health Policy
HEALTH POLICY Temporary Visitor Visas for Donating a KidneY This is a highly subjective list, but these trials have been included as they have had a meaningful impact on guidelines, patients and clinicians at a global scale. As a resident in the newly created...
Recent Comments